Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Quality control in manufacturing CAR-T cell therapies

Saskia Rösch • 6 Apr 2022
ICLE 2022
General CAR-T

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, describes methods to directly detect and isolate chimeric antigen receptor (CAR) derived from patient samples, including a CAR detection agent that enables the measurement of the transduction rate and presence of active CARs. The system can currently detect CD19, CD22, CD33, and B-cell maturation antigen (BCMA). Dr Rösch additionally highlights further tools to monitor the metabolome of CAR T-cells, which can be utilized in monitoring patient response. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Saskia Rösch

3:59
Strategies to improve CAR T-cell manufacturing
Saskia Rösch • 6 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals